PropThink: ILMN Getting a Lift From Roche Comments; Take-Out Possibility Remains
By David Moskowitz
We continue to believe that speculation that Roche (OTC: RHHBY) is back evaluating Illumina (NASDAQ: ILMN) as a take-out, is real, which you can read about in our prior story here. ILMN shares were off over 6% Monday, as investors saw the company hire a new head of investor relations, Rebecca Chambers, which was taken as a sign that ILMN would not be sold in the near term. We think this is ridiculous, and more importantly, Roche said on its earnings call Tuesday morning that it plans to continue investing in the gene sequencing segment. Of course, Roche CEO, Severin Schwan, declined to comment on speculation that the company might reconsider its bid for ILMN, but the prior run that Roche took at the company is telling. ILMN CEO Jason Flately has been vocal that a sale of the company is a possibility. We think that signals here are clear, and a Roche bid of $60 would not surprise us. Expect investors to take advantage of ILMN's weakness yesterday, with the stock up in early trading today on the Roche comments.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: PropThink via Thomson Reuters ONE